Research

Decorin: A Breakthrough Technology for Nervous System Repair

Stephen Davies PhD, Director, Spinal Cord Regeneration Program,

Florey Institute of Neuroscience & Mental Health.

Decorin Infusion: A promising technology for treating SCI

Traumatic spinal cord injury results in the loss of many neurons, support cells, and the failure of severed nerve fibres to regenerate across sites of injury and re-establish neural circuits. Inflammation promotes scarring at sites of injury and within surrounding tissues that actively inhibits sprouting of surviving nerve fibres and the formation of new neural circuits (“neuro-plasticity”). Award winning studies from the Davies research team have shown that infusion of a naturally occurring protein called Decorin into the spinal cord immediately after injury is highly effective at preventing the formation of inhibitory scar tissue, allowing nerve fibres to grow across Decorin treated injuries. In addition, the Davies lab have shown that Decorin can induce the injured spinal cord to make enzymes that can actively breakdown established scar tissue - results that have recently been independently replicated by a research team in the UK. Furthermore, the Davies team have also demonstrated that Decorin can have a direct effect on neurons to effectively “de-sensitize” their nerve fibres to growth inhibitory molecules found within scar tissue and throughout the environment of the chronically injured adult brain and spinal cord.

Turning a discovery into a therapy

In seeking means of delivering Decorin to patients, the team have recently discovered that infusion of human Decorin to cerebro-spinal fluid surrounding the brain and spinal cord in experimental studies can promote robust increases in nerve fiber sprouting, formation of new neural connections (called synapses) and recovery of locomotor function after SCI – even when administered to the chronically injured spinal cord. The ability of Decorin to suppress inflammation, scar formation, and promote extensive sprouting of neural circuits, strongly supports the development of Decorin infusion for treatment of a wide variety of other severe neurological disorders such as traumatic brain injury, cerebral palsy, hydrocephalus and stroke where these multiple benefits could be highly effective at promoting recovery of neural function. As Decorin protein is naturally found within the human nervous system but is suppressed after injury, infusion of the molecule to brain and spinal cord can be considered as being a "protein replacement” technology, much like providing insulin for diabetes patients. Unlike electro-stimulation therapies, infusion of Decorin can promote breakdown of scar tissue and the formation of new neural circuits in the chronic injured spinal cord. Unlike stem cell transplantation therapies which require complex surgeries and are limited in how many times patients can be treated, infusion of Decorin is a relatively simple procedure that could be combined with rehab and delivered multiple times to further improve recovery.

Importantly, having already worked closely with experienced biotech partners to establish a commercially viable source of pharmaceutical-grade human Decorin and intellectual property rights covering the infusion protocol, and thanks to funding support from Lions Australia for the research team at the Florey, the stage is set for delivering a breakthrough treatment for the injured nervous system that could have a profound effect on the quality of life of adults and children suffering with neurological disorders in Australia and around the world.

The LASCF committee will receive an update from our Fellowship holder every six months so that progress can be demonstrated.

( Stephen Davies PhD, is assistant to our Fellowship holder, Prof. Geoffrey Donnan, Director, Florey Institute of Neuroscience and Mental Health.)

For more information go to www.stepahead.org.au